Autoimmunity and immunotherapy for cancer

New England Journal of Medicine

Volumn 354, Issue 7, 2006, Pages 758-760

  Koon, Henry ^a   Atkins, Michael ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; RECOMBINANT ALPHA2B INTERFERON;

ANTINEOPLASTIC ACTIVITY; ARTHRITIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER RISK; CLINICAL TRIAL; DISEASE PREDISPOSITION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; EDITORIAL; ENTERITIS; HASHIMOTO DISEASE; HIGH RISK PATIENT; HUMAN; IMMUNOTOXICITY; MELANOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RISK BENEFIT ANALYSIS; THYROID DISEASE; TUMOR IMMUNITY; VASCULITIS; VITILIGO;

ADJUVANTS, IMMUNOLOGIC; AUTOANTIBODIES; AUTOIMMUNITY; CHEMOTHERAPY, ADJUVANT; HUMANS; IMMUNOTHERAPY; INTERFERON ALFA-2B; MELANOMA; SKIN NEOPLASMS;

EID: 32644477012     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe058307     Document Type: Editorial

References (12)

1. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004;351:998-1012.
2. [Erratum, N Engl J Med 2004;351:2461.]
3. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006;354:709-18.
4. Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 2005;23:307-36.
5. Atkins MB, Mier JW, Parkinson DR, Gould JA, Berkman EM, Kaplan MM. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med 1988;318:1557-63.
6. Atkins MB. Autoimmune disorders induced by interleukin-2 therapy. In: Atkins MB, Mier JW, eds. Therapeutic applications of interleukin-2. New York: Marcel Dekker, 1993:389-408.
7. Ribas A, Camacho LH, Lopez-Berenstein G, et al. Antitumor activity in melanoma and anti-self responses in a phase 1 trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 2005;23:8968-77.
8. Kristiansen OP, Larsen ZM, Pociot F. CTLA-4 in autoimmune diseases - a general susceptibility gene to autoimmunity? Genes Immun 2000;1:170-84.
9. Gambineri E, Torgerson TR, Ochs HD. Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis. Curr Opin Rheumatol 2003;15:430-5.
10. Atkins M, Regan M, McDermott D, et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005;11:3714-21.
11. Thompson RH, Gillett MD, Cheville JC, et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A 2004;101:17174-9.
12. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353:2135-47.